BioCryst
Pharmaceuticals BCRX and privately held Presidio
Pharmaceuticals today announced that the companies have signed
a definitive merger agreement for Presidio to be acquired by BioCryst in
an all-stock transaction. The transaction has been approved by the
Boards of both companies. The transaction values Presidio at
approximately $101 million, based on yesterday's closing BioCryst share
price of $4.11 per share. The transaction is expected to close in the
first quarter of 2013, and is subject to customary conditions, including
approval by BioCryst shareholders.
The merger creates a focused, clinical stage biopharmaceutical company
with lead programs in high-value infectious and orphan disease
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in